russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2018-5-56-60russjcardiol-2629Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESВЛИЯНИЕ ОМЕГА-3 ПОЛИНЕНАСЫЩЕННЫХ ЖИРНЫХ КИСЛОТ НА ЦИРКАДНЫЕ РИТМЫ ВАРИАБЕЛЬНОСТИ РИТМА СЕРДЦА ПРИ САХАРНОМ ДИАБЕТЕ 2 ТИПА И СЕРДЕЧНОЙ АВТОНОМНОЙ НЕЙРОПАТИИEFFECTS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS ON THE CIRCADIAN RHYTHM OF HEART RATE VARIABILITY PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR AUTONOMIC NEUROPATHYhttps://orcid.org/0000-0002-6414-0956СергиенкоВ. А.SerhiyenkoV. A.

Виктория Александровна Сергиенко — доктор медицинских наук, доцент кафедры эндокринологии

serhiyenko@inbox.ruhttps://orcid.org/0000-0002-8046-8011СегинВ. Б.SeginV. B.

Владимир Богданович Сегин  — врач-кардиолог

seginv@gmail.comhttps://orcid.org/0000-0002-3905-0326СергиенкоА. А.SerhiyenkoA. A.

Александр Алексеевич Сергиенко  — профессор кафедры эндокринологии

serhiyenkoa@gmail.comЛьвовский национальный медицинский университет имени Данила ГалицкогоУкраинаLviv National Medical University named after Danylo HalytskyUkraineЛьвовский областной государственный клинический лечебно-диагностический центр эндокринологииУкраина2Lviv Regional State Clinical Treatment and Diagnostic Endocrinology CenterUkraineЛьвовский национальный медицинский университет имени Д. ГалицкогоУкраинаLviv National Medical University named after Danylo HalytskyUkraine201802062018055660Copyright © Сергиенко В.А., Сегин В.Б., Сергиенко А.А., 20182018Сергиенко В.А., Сегин В.Б., Сергиенко А.А.Serhiyenko V.A., Segin V.B., Serhiyenko A.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/2629Цель

Цель. Проанализировать влияние a-3 полиненасыщенных жирных кислот (a-3 ПНЖК) на параметры вариабельности ритма сердца (ВРС) у пациентов с диабетом 2 типа (СД2) и развёрнутой стадией сердечно-сосудистой автономной полинейропатии (САП).

Материал и методы

Материал и методы. Мы изучили данные 36 пациентов с СД2 и развёрнутой стадией САП, возраст 50-59 лет, с длительностью заболевания 1-6 лет с медианой уровня гликированного гемоглобина 71%±0,12%. Пациенты были разделены на 2 группы. Первая группа получала стандартную гипогликемическую терапию (n=15, контроль); пациенты из группы 2 (n=21) получали дополнительно1 г в день a-3 ПНЖК в течение 3 месяцев.

Результаты

Результаты. Назначение a-3 ПНЖК пациентам с СД2 и развёрнутой стадией САП сопровождалось статистически значимым увеличением временных параметров ВРС; спектральные параметры ВРС в активный и пассивный периоды были сравнимы с таковыми у контроля.

Заключение

Заключение. Полученные результаты предполагают, что эффективность a-3 ПНЖК является результатом прямого влияния a-3 ПНЖК на изученные показатели.

Aim

Aim. The aim of the study was to analyze the effect of a-3 polyunsaturated fatty acids (a-3 PUFAs) on the heart rate variability (HRV) parameters in patients with type 2 diabetes mellitus (T2DM) and advanced stage of cardiovascular autonomic neuropathy (CAN).

Material and methods

Material and methods. We have examined 36 patients with T2DM and advanced stage of CAN, aged between 50-59 years with disease duration 1-6 years and median glycated hemoglobin A1c 71%±0,12%. Patients with T2DM and advanced stage of CAN were divided into 2 groups. The first group received traditional antihyperglycemic therapy (n=15, control) for three mo; patients in group 2 (n=21) received in addition 1 g/day of the a-3 PUFAs for three months.

Results

Results. Prescription of the a-3 PUFAs to the patients with T2DM and advanced stage of CAN was accompanied by a statistically significant increase of the timedomain HRV parameters; the spectral HRV parameters during the active and passive periods compared to the control group.

Conclusion

Conclusion. Obtained results suggest that the efficacy of a-3 PUFAs is the result of a direct effect of the a-3 PUFAs on the investigated indexes.

сахарный диабет 2 типасердечно-сосудистая автономная нейропатияtype 2 diabetes mellituscardiovascular autonomic neuropathyReferencesAmerican Diabetes Association. Standards of medical care in diabetes-2017. Diabetes Care 2017; 40:1-132.American Diabetes Association. Standards of medical care in diabetes-2017. Diabetes Care 2017; 40:1-132.Vinik AI, Erbas T, Casellini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig 2013; 4: 4-18.Vinik AI, Erbas T, Casellini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig 2013; 4: 4-18.Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management on behalf of The Toronto Consensus panel on diabetic neuropathy. Diabetes Metab Res Rev 2011; 27: 639-53.Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management on behalf of The Toronto Consensus panel on diabetic neuropathy. Diabetes Metab Res Rev 2011; 27: 639-53.Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes 2014; 5: 17-39.Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes 2014; 5: 17-39.Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: A position statement by the American Diabetes Association. Diabetes Care 2017; 40: 136-54.Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: A position statement by the American Diabetes Association. Diabetes Care 2017; 40: 136-54.Silva-e-Oliveira J, Amelio PM, Abranches IL, et al. Heart rate variability based on risk stratification for type 2 diabetes mellitus. Einstein 2017; 15: 141-7.Silva-e-Oliveira J, Amelio PM, Abranches IL, et al. Heart rate variability based on risk stratification for type 2 diabetes mellitus. Einstein 2017; 15: 141-7.Balcioglu AS, Muderrisoglu H. Diabetes and cardiac autonomic neuropathy: clinical manifestations, cardiovascular consequences, diagnosis and treatment. World J Diabetes 2015; 6: 80-91.Balcioglu AS, Muderrisoglu H. Diabetes and cardiac autonomic neuropathy: clinical manifestations, cardiovascular consequences, diagnosis and treatment. World J Diabetes 2015; 6: 80-91.Serhiyenko VA, Serhiyenko LM, Serhiyenko AA. Omega-3 polyunsaturated fatty acids in the treatment of diabetic cardiovascular autonomic neuropathy: A review. In: Moore SJ, ed. Omega-3: Dietary sources, biochemistry and impact on human health. New York: Nova Science Publishers, 2017: 79-154).Serhiyenko VA, Serhiyenko LM, Serhiyenko AA. Omega-3 polyunsaturated fatty acids in the treatment of diabetic cardiovascular autonomic neuropathy: A review. In: Moore SJ, ed. Omega-3: Dietary sources, biochemistry and impact on human health. New York: Nova Science Publishers, 2017: 79-154).Adamec J, Adamec R. ECG Holter. Guide to electrocardiographic interpretation. New York; London: Springer Science & Business Media, 2008. p. 90.Adamec J, Adamec R. ECG Holter. Guide to electrocardiographic interpretation. New York; London: Springer Science & Business Media, 2008. p. 90.Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim Biophis Acta 2015; 1851: 469-84.Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim Biophis Acta 2015; 1851: 469-84.Endo J, Arita M. Cardioprotective mechanism of omega-3 polyunsaturated fatty acids. J Cardiol 2016; 67: 22-7.Endo J, Arita M. Cardioprotective mechanism of omega-3 polyunsaturated fatty acids. J Cardiol 2016; 67: 22-7.Christensen JH. Omega-3 polyunsaturated fatty acids and heart rate variability. In: Billman GE, ed. The effects of omega-3 polyunsaturated fatty acids on cardiac rhythm: antiarrhythmic, proarrhythmic, both or neither? Lausanne CH: Frontiers Media SA, 2013: 9-17.Christensen JH. Omega-3 polyunsaturated fatty acids and heart rate variability. In: Billman GE, ed. The effects of omega-3 polyunsaturated fatty acids on cardiac rhythm: antiarrhythmic, proarrhythmic, both or neither? Lausanne CH: Frontiers Media SA, 2013: 9-17.Bilman GE. The effects of omega-3 polyunsaturated fatty acids on cardiac rhythm: a critical reassessment. Pharmacol Ther 2013; 140: 53-80.Bilman GE. The effects of omega-3 polyunsaturated fatty acids on cardiac rhythm: a critical reassessment. Pharmacol Ther 2013; 140: 53-80.Bradberry JC, Daniel E, Hilleman DE. Overview of omega-3 fatty acid therapies. P T. 2013; 38: 681-91.Bradberry JC, Daniel E, Hilleman DE. Overview of omega-3 fatty acid therapies. P T. 2013; 38: 681-91.

The authors declare that there are no conflicts of interest present.